Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)
Phase 4
- Conditions
- ovel Coronavirus Pneumonia (COVID-19)
- Registration Number
- ITMCTR2000003105
- Lead Sponsor
- The First People's Hospital of Jiangxia District, Wuhan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Temporary halt
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. Novel coronavirus pneumonia is diagnosed met the fifth edition of the national health and Health Committee;
2. Respiratory rate in calm state >=30 times / min; OR Finger pulse oxygen saturation under rest and non oxygen absorption state <=93%; OR PO2/FiO2)<=300mmHg; OR PO2<60mmHg.
Exclusion Criteria
1. Aged < 7-year-old;
2. previous arrhythmia;
3. previous chronic respiratory failure caused by other diseases, such as heart failure, thoracic deformity, structural lung disease, etc.;
4. hemodynamic instability;
5. severe immune deficiency or recent use of immunosuppressive agents;
6. allergic patients;
7. estimated survival time less than 3 days;
8. dropout on the halfway as well as lose of follow-up.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ROX INDEX;PO2/FiO2;
- Secondary Outcome Measures
Name Time Method Time of Support time;WBC;PBML;